DISEASE&TOPICS | AP-NDI-AP-NDI

About AP-NDI

DISEASE&TOPICS

Public-Education Series: What Is the Treatment for Dengue?

Unlike many common viral infections, dengue fever currently has no specific antiviral medication that directly targets the dengue virus itself. This means treatment focuses entirely on supportive care, symptom relief, and vigilant monitoring to prevent progression to severe dengue.
Public-Education Series: What Are the Symptoms of Dengue Fever and Severe Dengue?

Dengue fever typically begins after an incubation period of 4 to 10 days following the bite of an infected mosquito, with symptoms that closely resemble a severe flu but follow a distinct and often debilitating progression over 2 to 7 days.
Public-Education Series: Where Does Dengue and Severe Dengue Occur?

Dengue, once considered a geographically contained tropical disease, has dramatically expanded its global footprint over recent decades and is now firmly established as a year-round threat across virtually all tropical regions worldwide.
Public-Education Series: What Is Dengue and Severe Dengue?

Dengue, a mosquito-borne viral infection found across tropical and subtropical regions worldwide, is one of the fastest-growing global public health challenges of our time, with its global incidence skyrocketing by an astonishing 30-fold over the past half-century.
Public‑Education Series：Should Tourists Be Concerned When Traveling to Countries That Have Schistosomiasis?

For millions of international travelers planning trips to tropical and subtropical destinations across Africa, Southeast Asia, and parts of Latin America, the question of whether to worry about schistosomiasis often pops up in pre-travel health research
Public-Education Series: Can Schistosomiasis Be Treated?

For decades, schistosomiasis was seen as a persistent, hard-to-manage neglected tropical disease that left millions of people in endemic regions facing lifelong progressive organ damage with few accessible solutions.
Public-Education Series: How Do Children Get Exposed for Schistosomiasis?

School-aged children are among the highest-risk groups for schistosomiasis infection in endemic regions, and their unique daily behaviors, developmental traits, and limited access to protective resources make them far more vulnerable to the disease than many adult populations.
Public-Education Series: What Are the Symptoms of Urogenital Schistosomiasis?

Urogenital schistosomiasis, a chronic parasitic infection caused by the blood fluke Schistosoma haematobium, is one of the most underrecognized public health threats in tropical and subtropical endemic regions, with its symptoms often unfolding slowly over years of unaddressed infection.
Public-Education Series: What Are the Forms of Schistosomiasis or Bilharzia?

Schistosomiasis, the widespread neglected tropical parasitic disease transmitted by freshwater snails, is broadly categorized into two major clinical forms: intestinal schistosomiasis and urogenital schistosomiasis.
Public-Education Series: What Is Schistosomiasis or Bilharzia?

Schistosomiasis, also widely known as bilharzia, is a neglected tropical acute and chronic parasitic disease caused by flatworms of the genus Schistosoma.
Public-Education Series: What Is the WHO Doing Now to Fight Malaria in Areas Hardest Hit by Malaria?

For decades, global malaria control efforts have followed a one-size-fits-all model, distributing bed nets, medications and vaccines across broad regions without fully centering the unique realities of the communities bearing the brunt of the disease.
Public-Education Series: Why Is It Taking So Long to Eradicate Malaria?

Malaria has remained one of humanity’s most persistent public health battles, and the question of why global eradication efforts are taking far longer than once predicted touches on every layer of biology, society, and public health infrastructure.
Public-Education Series: Can Malaria Be Truly Eradicated?

Based on its comprehensive, multi-year analysis, the World Health Organizations Strategic Advisory Group on Malaria Eradication (SAGme) concluded that ‌malaria can, in principle, be truly eradicated.‌ This means that, like smallpox, it is biologically and technically plausible to achieve a permanent, global zero incidence of the disease, with no risk of reintroduction.
Public-Education Series: What Is the Difference Between Malaria Elimination and Eradication?

The precise, operational definition of what constitutes “malaria elimination” versus “malaria eradication” has evolved significantly over the decades, shaped by lessons from past campaigns, advances in surveillance science, and a deepening understanding of the complex biology of the Plasmodium parasite.
Public-Education Series: Why Did WHO Establish a Strategic Advisory Group on Malaria Eradication (SAGme)?

The former Director-General of the World Health Organization, Dr. Margaret Chan, recognized that the time had come to confront one of the most ambitious, complex, and debated questions in global public health: the possibility of eradicating malaria entirely from the world, once and for all.
Public-Education Series: How Is WHO Responding to the Emergence of Partial Artemisinin Resistance in Africa?

The independent emergence of artemisinin partial resistance across multiple countries in Africa, a continent that bears over 90% of the world’s total malaria burden, has created an urgent public health imperative for a coordinated, proactive global respons
Public-Education Series: How Is WHO Supporting Countries in the Greater Mekong Subregion Tackle Multidrug Resistance?

In the Greater Mekong Subregion (GMS), where overlapping threats of artemisinin partial resistance and partner drug resistance once threatened to unravel decades of hard-won progress against malaria, the coordinated public health response has centered on two core, mutually reinforcing pillars
Public-Education Series: What Is the Current State of ACT Failures Around the World?

The effectiveness of every WHO-recommended Artemisinin-based Combination Therapy (ACT) around the world is rigorously evaluated through standardized, gold-standard research known as therapeutic efficacy studies, or TES for short.
Public-Education Series: What Is the State of Partial Artemisinin Resistance Around the World?

lear, well-documented evidence of malaria parasites that carry partial resistance to artemisinin has now been officially identified across two major global malaria hotspots: the entire Greater Mekong Subregion (GMS) in Southeast Asia, and multiple countries in sub-Saharan Africa, specifically Eritrea, Rwanda, Uganda, and the United Republic of Tanzania.
Public‑Education Series：What‘s Artemisinin partial resistance？

Artemisinin partial resistance, a growing public health concern first identified in Southeast Asia more than a decade ago, typically refers to a measurable delay in the clearance of malaria parasites from a patient’s bloodstream

Total: 3 Current:2 << < 123 > >>